by s2desi5_voyagertherapeutics | Aug 30, 2023 | Uncategorized |
CAMBRIDGE, Mass. , Aug. 30, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following...
by s2desi5_voyagertherapeutics | Aug 8, 2023 | Uncategorized |
CAMBRIDGE, Mass. , Aug. 08, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with Beth Shafer , Ph.D., M.A.,...
by s2desi5_voyagertherapeutics | Aug 7, 2023 | Uncategorized |
CAMBRIDGE, Mass. , Aug. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics , Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer , Ph.D., M.A., M.Phil .,...
by s2desi5_voyagertherapeutics | Aug 3, 2023 | Uncategorized |
– Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio – – Executed license agreement with Sangamo for prion disease treatment – – Presented validating preclinical results...
by s2desi5_voyagertherapeutics | Aug 2, 2023 | Uncategorized |
CAMBRIDGE, Mass. , Aug. 02, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Scientific Officer Todd Carter , Ph.D., and...
